A patent review of NLRP3 inhibitors to treat autoimmune diseases

Although significant advances have been made in understanding the NLRP3 inflammasome, more studies are still needed to elucidate the molecular mechanisms ...

The current review summarizes the functional facets of the NLRP3 inflammasome, its association with autoimmune diseases, and recent patents on the development ...

A Patent Review of NLRP3 Inhibitors to Treat Autoimmune Diseases

The current review summarizes the functional facets of the NLRP3 inflammasome, its association with autoimmune diseases, and recent patents on the development ...

A patent review of NLRP3 inhibitors to treat autoimmune diseases

Expert opinion. Although significant advances have been made in understanding the NLRP3 inflammasome, more studies are still needed to elucidate the molecular ...

A Patent Review of NLRP3 Inhibitors to Treat Autoimmune Diseases

A number of NLRP3 inhibitors have been patented, however, none of them have been approved for clinical use. Due to the complex nature of the NLRP3 inflammasome, ...

US20200361898A1 - Nlrp3 inflammasome inhibitors - Google Patents

... treatment of diseases and disorders mediated by NLRP3 ... a disease or disorder selected from inflammasome-related disease/disorders, immune diseases ...

Patent Highlights: NLRP3 and NaV1.8 Inhibitors, SMARCA2 ...

... therapeutic benefit in cancer and autoimmune diseases. GSK Reports Macrocyclic NaV1.8 Inhibitors. GlaxoSmithkline published a patent ...

Expert Opin Ther Pat - Publication Information - Medscape

A patent review of NLRP3 inhibitors to treat autoimmune diseases. January 01, 2023. [ MEDLINE Abstract ]. « Previous · Next » ...

NLRP3: A promising therapeutic target for autoimmune diseases.

Hui-Hui Shen, Yue Yang, +5 authors. Hai-Feng Pan · Published in Autoimmunity Reviews 1 July 2018 · Medicine.

Therapeutic potential of MCC950, a specific inhibitor of NLRP3 ...

This comprehensive review delves into the characteristics of SLE as an autoimmune disease and its relationship with the NLRP3 inflammasome. In SLE, NLRP3 is ...

Regulating the NLRP3 Inflammasome in Autoimmune Diseases

In recent years, a number of bioactive substances have shown new potentiality for regulating the NLRP3 inflammasome in autoimmune diseases. This review provides ...

NLRP3: A promising therapeutic target for autoimmune diseases

In this review, we will briefly discuss the biological features of NLRP3 and summarize the recent progression of the involvement of NLRP3 in the development and ...

The NLRP3 Inflammasome Pathway: A Review of Mechanisms and ...

Studies using small molecules and biologics targeting the NLRP3 inflammasome pathway have shown positive outcomes in treating various disease pathologies by ...

New NLRP3 inflammasome inhibitors disclosed in Ventus ...

Ventus Therapeutics US Inc. has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, metabolic diseases, autoimmune ...

1,2,4-Triazine Derivatives as NLRP3 Inhibitors for Treating Diseases

Inflammasomes are part of the innate immune system. Inflammasome activation is initiated by assembly of a multiprotein complex, including a ...

Targeting the NLRP3 inflammasome as new therapeutic avenue for ...

Because of its exclusive activation upon inflammatory stimuli, NLRP3 is intensively pursuit as a promising drug target for the treatment of autoimmune and ...

NLRP3 Inflammasome Inhibitors and AI-Driven Predictive Health ...

As such, the discovery of NLRP3 inhibitors opens new avenues for treating diseases where inflammation is a key driver. These small-molecule ...

NLRP3 inflammasome and its inhibitors: a review - Frontiers

Krishnan et al. (2015) demonstrated that hypertension in mice treated with salt and deoxycorticosterone acetate can be reversed by treating them with MCC950, ...

New NLRP3 inflammasome inhibitors disclosed in Merck Sharp ...

... inflammatory skin disease, inflammatory joint disease, autoimmune disease, Alzheimer's disease and Parkinson's disease, among others.

A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and ...

The primary focus of this review is RRx-001 (generic name bromonitrozidine) and its therapeutic potential for NLRP3-driven inflammatory diseases ...